Related Experiment Video
Updated: Jun 10, 2026
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
[Expression and its clinical significance of SHP2 in non-small cell lung cancer]
Chunlan Tang1, Xiangdong Zhou, Heping Yang
1Department of Respiratory, Southwest Hospital, Third Military Medical University, Chongqing 400038, China.
Background And Objective:
Precious studies proven that aberrant tyrosine phosphorylation has linked with cancer. The aim of this work is to study the expression and significance of SHP2 in non-small cell lung cancer (NSCLC) through tissue microarray technique and immunohistochemical method.
Methods:
Eighty NSCLC specimens were constructed into tissue microarray and performed using immunohistochemistry.
Results:
The total positive rates of SHP2 were 70.7% (56/80) in NSCLC, 72.5% (29/40) in squamous cell carcinoma and 75% (27/40) in adenocarcinoma, which was not significant difference in sex, age, the size of tumor, histology, clinical stages and differentiation (P > 0.05), the positive rates of SHP2 were significantly higher in the cases with lymphnode metastasis than those without (P < 0.05).
Conclusion:
The expression rate of SHP2 is high and closely correlated to lymphnode metastasis in NSCLC, which implies the occurrence and development of lung cancer maybe related to SHP2, and SHP2 maybe a new marker and therapeutic targets for lung cancer.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
02:23Abnormal Proliferation